Appropriate Use of Levofloxacin

Introduction to Levofloxacin Use

The Centers for Disease Control and Prevention recommends levofloxacin should not be used as a first-line agent for most bacterial infections and must be reserved for drug-resistant organisms, first-line drug intolerance, or specific severe infections where benefits clearly outweigh risks 1, 2

The American Academy of Pediatrics notes that overall resistance of Gram-negative organisms in pediatrics, including Pseudomonas aeruginosa, has been <5%, except in cystic fibrosis patients 3
The Centers for Disease Control and Prevention reports that E. coli resistance to ciprofloxacin (and by extension, levofloxacin) ranges from 4-7% at major tertiary care centers as of 2010, with rates stable over the preceding 3 years 3
Cross-resistance is demonstrated among ciprofloxacin, ofloxacin, and levofloxacin—presumed to be a class effect 1, 2, 4

The World Health Organization recommends levofloxacin as a preferred oral fluoroquinolone for MDR-TB when organisms are known or presumed sensitive 1, 2, 4
The Infectious Diseases Society of America indicates levofloxacin is appropriate for community-acquired pneumonia in adults with comorbidities or when S. pneumoniae resistance to macrolides/penicillins is documented 5
The European Society of Clinical Microbiology and Infectious Diseases suggests levofloxacin for complicated urinary tract infections when antibiogram shows resistance to first-line agents or Pseudomonas involvement 5, 3

The Centers for Disease Control and Prevention recommends dosing adjustments for renal impairment, with no adjustment needed for CrCl ≥50 mL/min, and adjustment to 750-1,000 mg three times weekly for CrCl <50 mL/min 1, 2, 4

The Centers for Disease Control and Prevention notes that common adverse effects include gastrointestinal symptoms in 0.5-1.8% of patients, neurologic effects in 0.5%, and cutaneous effects in 0.2-0.4% 1, 2
The FDA warns of serious but rare adverse effects, including tendinitis and tendon rupture associated with long-term fluoroquinolone use 6
The Centers for Disease Control and Prevention advises on potential drug interactions, including absorption interference with antacids, sucralfate, multivitamins with zinc, iron supplements, and divalent cations, which can be mitigated by a 2-hour separation rule 1, 2, 4

The Centers for Disease Control and Prevention, as reported in MMWR Recommendations and Reports, recommends that fluoroquinolones, including levofloxacin, should not be considered first-line agents except in patients who are intolerant of first-line drugs 7
The Infectious Diseases Society of America, as published in Clinical Infectious Diseases, recommends levofloxacin and other respiratory fluoroquinolones for community-acquired pneumonia in adults with comorbidities 8

The Centers for Disease Control and Prevention, as reported in MMWR Recommendations and Reports, advises that fluoroquinolones should be avoided in pregnancy due to potential teratogenic effects, and the long-term use of fluoroquinolones in children and adolescents is not generally approved due to concerns about effects on bone and cartilage growth 7
Common adverse effects of levofloxacin include gastrointestinal disturbances in 0.5-1.8% of patients, neurologic effects in 0.5% of patients, and cutaneous reactions in 0.2-0.4% of patients, as reported in MMWR Recommendations and Reports 7
For patients with penicillin allergy, the British Infection Association, as published in the Journal of Infection, recommends alternative treatments such as macrolides like clarithromycin or erythromycin, and tetracyclines in appropriate age groups 9

The American College of Physicians and Infectious Diseases Society of America recommend levofloxacin as the preferred agent for antibacterial prophylaxis during severe neutropenia in pediatric cancer patients and hematopoietic stem cell transplantation recipients, with strong recommendation and moderate-quality evidence 10, 11, 12
The Infectious Diseases Society of America suggests that levofloxacin's broad-spectrum activity against pathogens responsible for severe or difficult-to-treat infections, including superior activity against gram-positive bacteria, makes it a preferred choice for severe neutropenic infections 10, 12
Recent large pediatric trials demonstrated clear benefits in reducing bacteremia during high-risk neutropenic periods, supporting the use of levofloxacin in this context 10
The Centers for Disease Control and Prevention emphasize the importance of informing patients and families about potential short- and long-term fluoroquinolone-related adverse effects before administration of levofloxacin 10, 11, 12

The World Health Organization recommends excluding levofloxacin and moxifloxacin from treatment guidelines for COPD exacerbations due to fluoroquinolone side effects and emergence of resistance 13
The World Health Organization suggests that levofloxacin should not be used as a first-line agent for most bacterial infections, and must be reserved for drug-resistant organisms, first-line drug intolerance, or specific severe infections where benefits clearly outweigh risks 13

The Infectious Diseases Society of America recommends that levofloxacin's use is justified when life-threatening infections exist where resistance patterns or patient factors preclude safer alternatives, and when severe neutropenia places patients at immediate risk of fatal bacteremia 10, 11
The Centers for Disease Control and Prevention emphasize the importance of weighing short-term benefits in reducing bacteremia and febrile neutropenia against long-term consequences of increasing resistance rates in individual patients and institutions 10, 11
The Infectious Diseases Society of America suggests that institutions must closely monitor resistance rates over time if prophylaxis with levofloxacin is implemented 10

The American Academy of Pediatrics recommends levofloxacino as the preferred agent for antibacterial prophylaxis in children with cancer and hematopoietic stem cell transplant recipients during severe neutropenia (absolute neutrophil count <500/μL), based on strong evidence from contemporary pediatric data and its microbiological activity spectrum, including superior activity against gram-positive bacteria 14
For patients with multiple myeloma receiving bispecific antibody therapy, levofloxacino is recommended for antibacterial prophylaxis in patients with prolonged neutropenia or a history of recurrent bacterial infections 15

The Infectious Diseases Society of America strongly recommends against the use of fluoroquinolones, including levofloxacino, for streptococcal pharyngitis due to limited activity and high cost 14